Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor
about
Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted miceSoluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesImpact of soluble epoxide hydrolase and epoxyeicosanoids on human healthPharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitorCytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaquesMammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolaseStabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancerAttenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signalingEndothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in micePossible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disordersSoluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitorRed blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP)Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammationInhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammationBioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposureThe 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic painCytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammationEpoxides and soluble epoxide hydrolase in cardiovascular physiologyInhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine modelPharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsInhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory painSoluble epoxide hydrolase is a therapeutic target for acute inflammationMacrophage epoxygenase determines a profibrotic transcriptome signature.The cloning and characterization of a soluble epoxide hydrolase in chicken.Development of a high-throughput screen for soluble epoxide hydrolase inhibitionEH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides.11,12-Epoxyeicosatrienoic acid induces vasodilator response in the rat perfused mesenteric vasculature.Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in miceThe role of epoxide hydrolases in health and disease.Genetic polymorphisms in arginase I and II and childhood asthma and atopyLipoxin generation is related to soluble epoxide hydrolase activity in severe asthmaThe anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment.Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice.2,3,7,8-Tetrachlorodibenzo-p-dioxin treatment alters eicosanoid levels in several organs of the mouse in an aryl hydrocarbon receptor-dependent fashionPrevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase.Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols.Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.
P2860
Q23910189-A4F5F054-BC1A-4ADD-B8B6-9EA518552DD7Q24597172-CBD68657-341F-4649-88F5-3975D5E75EEBQ24618018-C000C83C-7B01-4604-BC87-E53773E7560CQ28270421-B93507AF-E696-46D5-AE01-7AD00DA3EE12Q28281019-BB59A4EA-A320-4E4D-B6A6-7D90BF25589FQ28302779-F092E9EB-F563-4644-ABEE-52C1210BDA12Q28304230-E9B5059E-90EF-4079-B6A5-9B8FF40681BEQ28385015-BC202A32-91F9-4BEE-9F83-B0449EC51AE4Q28385835-5DC45ABD-BF34-4C00-9774-70EADF2FAEDAQ28386662-75C1F334-66B4-457A-8A54-052E27C1E2F2Q28387686-157D39C4-F386-4C94-A705-2EF2DEC00EB3Q28388012-5D5ED7EF-8A3D-4BBE-B0A1-F831D19A593FQ28389323-4EFBEB84-1535-4289-8E1A-BD7A52A3A88CQ28391533-E26F2954-B07B-448F-A456-DAA815D18B9EQ28391885-0B37EEF8-9F40-45C7-B7D2-1BD59A8D9082Q28392416-477BE873-7456-4AA3-9405-8E18491E2420Q28393303-11692D0C-5364-4D35-8E13-12F4C4B4A2C5Q28396313-9D758BA4-E908-4C75-87CB-3F454A671502Q28396881-22495F4C-C4FA-4DD1-A318-6F213049A43AQ28396888-645EF4CC-582F-453B-81FF-37C01302E650Q28564290-9F166E94-67F2-4017-B7FE-B24C10D6AB66Q29620593-E094B908-4E54-41A3-BB42-B98D73310FADQ30273952-67528717-5C6A-49D6-AB96-E57DAB4F8FDBQ30445450-6EB5C510-5C70-496E-9B38-F46ABF22FD18Q30816822-8EBE0612-313E-4DC7-A7C9-0D2F150DDA66Q33288850-E8751F12-F249-4EE9-B00D-B5A22B3E4934Q33578326-E39FC126-95F7-4D36-8440-E7C19F9007B7Q33814824-3B03C49B-31B5-4770-AE06-AEBA08715CE3Q34339690-E507D73D-D9E6-4625-A15E-508ACE3C0EE7Q34440084-8AED214C-63FD-488E-BC89-AD76A231F3FEQ34574103-10AB878B-9E36-4FBB-AF7E-DC0592D444E9Q34986906-3EB2373E-D12E-46BE-97A0-2F1A30E130E6Q35196023-CD6BBCB0-30EE-4D03-892F-89AD70EB2E08Q35207683-AB1860A6-A0FF-463D-84A6-AA860D0CD4E0Q35783207-6D3779A9-8587-42D3-8D2C-5CB963E60B57Q35842836-743D73DA-58DA-481E-AF8C-981932E1818FQ35865405-CA2B5618-B9E4-4760-A11F-4055D59F6913Q35987189-918A6B01-ABA4-423E-879A-E2587BB461BDQ36056415-7B3751C0-6D9D-4659-83F2-DA1E4F327C16Q36124088-2C549244-6BC0-46C8-A6E5-2072E5D6F598
P2860
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor
description
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 2005
@ast
im Februar 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/02/08)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/02/08)
@nl
наукова стаття, опублікована в лютому 2005
@uk
name
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@ast
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@en
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@nl
type
label
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@ast
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@en
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@nl
prefLabel
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@ast
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@en
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@nl
P2093
P2860
P3181
P356
P1476
Attenuation of tobacco smoke-i ...... le epoxide hydrolase inhibitor
@en
P2093
Bruce D. Hammock
Kent E. Pinkerton
Kevin R. Smith
Seung Jin Ma
Takaho Watanabe
Theresa L. Pedersen
P2860
P304
P3181
P356
10.1073/PNAS.0409591102
P407
P577
2005-02-08T00:00:00Z